Description
GRC-17536 is an orally available, potent, and selective transient receptor potential anchor protein 1 (TRPA1) inhibitor that has been shown to be highly effective in the treatment of inflammation and neuropathic pain in animal models. The selectivity of GRC-17536 is more than 1000 times higher than that of other TRPs, uMerous GPCRs, enzymes, and other ion channels